209 related articles for article (PubMed ID: 11549491)
1. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria.
Bartsch G; Horninger W; Klocker H; Reissigl A; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P;
Urology; 2001 Sep; 58(3):417-24. PubMed ID: 11549491
[TBL] [Abstract][Full Text] [Related]
2. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
3. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Curr Urol Rep; 2004 Jun; 5(3):220-5. PubMed ID: 15161571
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
5. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality.
Bartsch G; Horninger W; Klocker H; Pelzer A; Bektic J; Oberaigner W; Schennach H; Schäfer G; Frauscher F; Boniol M; Severi G; Robertson C; Boyle P;
BJU Int; 2008 Apr; 101(7):809-16. PubMed ID: 18321314
[TBL] [Abstract][Full Text] [Related]
6. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing.
Oberaigner W; Horninger W; Klocker H; Schönitzer D; Stühlinger W; Bartsch G
Am J Epidemiol; 2006 Aug; 164(4):376-84. PubMed ID: 16829552
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.
Oberaigner W; Siebert U; Horninger W; Klocker H; Bektic J; Schäfer G; Frauscher F; Schennach H; Bartsch G
Int J Public Health; 2012 Feb; 57(1):57-62. PubMed ID: 21681451
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
9. PSA testing in Austria: induced morbidity and saved mortality.
Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
[TBL] [Abstract][Full Text] [Related]
10. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.
Reissigl A; Horninger W; Fink K; Klocker H; Bartsch G
Cancer; 1997 Nov; 80(9):1818-29. PubMed ID: 9351555
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer and prostate-specific antigen testing in New South Wales.
Smith DP; Supramaniam R; Marshall VR; Armstrong BK
Med J Aust; 2008 Sep; 189(6):315-8. PubMed ID: 18803534
[TBL] [Abstract][Full Text] [Related]
12. Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program.
Heidegger I; Fritz J; Klocker H; Pichler R; Bektic J; Horninger W
PLoS One; 2015; 10(7):e0134134. PubMed ID: 26218594
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
14. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
Pelzer AE; Tewari A; Bektic J; Berger AP; Frauscher F; Bartsch G; Horninger W
Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118
[TBL] [Abstract][Full Text] [Related]
15. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
16. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
Collin SM; Martin RM; Metcalfe C; Gunnell D; Albertsen PC; Neal D; Hamdy F; Stephens P; Lane JA; Moore R; Donovan J
Lancet Oncol; 2008 May; 9(5):445-52. PubMed ID: 18424233
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality.
Vutuc C; Waldhoer T; Madersbacher S; Micksche M; Haidinger G
Eur J Cancer Prev; 2001 Oct; 10(5):425-8. PubMed ID: 11711757
[TBL] [Abstract][Full Text] [Related]
18. Self-reported prostate cancer screening in Austria.
Vutuc C; Waldhoer T; Sevelda P; Micksche M; Haidinger G
J Med Screen; 2006; 13(3):148-51. PubMed ID: 17007656
[TBL] [Abstract][Full Text] [Related]
19. Mortality results from a randomized prostate-cancer screening trial.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Gelmann EP; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Clapp JD; Rathmell JM; Riley TL; Hayes RB; Kramer BS; Izmirlian G; Miller AB; Pinsky PF; Prorok PC; Gohagan JK; Berg CD;
N Engl J Med; 2009 Mar; 360(13):1310-9. PubMed ID: 19297565
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer.
Ito K; Yamamoto T; Kubota Y; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
Urology; 2000 Aug; 56(2):278-82. PubMed ID: 10925094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
